Microespheres as delivery systems for the controlled release of peptides and proteins;Las microesferas como sistemas de liberación controlada de péptidos y proteínas

Biotecnologia Aplicada

Volumn 24, Issue 2, 2007, Pages 98-107

  Saez, Vivian ^a   Hernández, José Ramón ^a   Peniche, Carlos ^b  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b UNIVERSITY OF HAVANA   (Cuba)

Author keywords

Controlled release; Microspheres; PLGA; Protein delivery

Indexed keywords

ABARELIX; BECAPLERMIN; BETA1A INTERFERON; ESTREPTASA; GLYCOLIC ACID; HEBERKINASA; HEBERON ALFA R; HUMAN GROWTH HORMONE; HUMAN INSULIN; LEUPRORELIN; MICROSPHERE; OCTREOTIDE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TRIPTORELIN;

ACROMEGALY; ACUTE HEART INFARCTION; ANEMIA; CONTROLLED RELEASE FORMULATION; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STERILITY; EMULSION; ENDOCRINE TUMOR; EVAPORATION; GROWTH HORMONE DEFICIENCY; HAIRY CELL LEUKEMIA; HEPATITIS B; HEPATITIS C; HUMIDITY; KAPOSI SARCOMA; KIDNEY CANCER; LEG ULCER; LUNG CANCER; MATERIAL COATING; MICROENCAPSULATION; MULTIPLE SCLEROSIS; NEUTROPENIA; PANCREAS TUMOR; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROSTATE CANCER; REVIEW; STOMACH TUMOR;

EID: 43649089507     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Johnson OL, Jaworowicz W, Cleland J, Bailey L, Charnis M, Duenas E, et al. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm Res (1997); 14:730-5.
2. Jones AJ, Putney S, Johnson OL, Cleland J. Recombinant human growth hormone poly (lactic-co-glycolic acid) microsphere formulation development. Adv Drug Deliv Rev (1997); 28:71-84.
3. Langer R. Drug delivery and targeting. Nature (1998); 392:5-10.
4. Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother (2000); 34:915-23.
5. Davis F. The origin of pegnology. Adv Drug Deliv Rev (2002); 54:457-8.
6. Allen TA. Liposomes. Opportunities in drug delivery. Drugs (1997); 54:8-14.
7. Remuñán C, Alonso MJ. Microencapsulación de medicamentos. En: Vilá-Jato JL. Tecnología Farmacéutica. Aspectos fundamentales de los sistemas farmacéuticos y operaciones básicas. Madrid: Ed. Síntesis, SA; 1997:577-609.
8. Gilding PAR, Reed AM. Biodegradable polymers for use in surgery polyglycolic/ polylactic homo and copolymers 2. in vitro Degradation. Polymer (1981); 22:467-79.
9. Tamber H, Johansen P, Merkle HP, Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev (2005); 57:357-76.
10. Göpferich A. Mechanisms of polymer degradation and erosion. Biomaterials (1996); 17:103-14.
11. Visscher GE, Robinson RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. Biodegradation of and tissue reaction to 50:50 poly(D,L-lactide-co- glycolide) microcapsules. J Biomed Mater Res Part A (1985); 19:349-65.
12. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials (1996); 17:93-102.
13. Eppley BL. Use of resorbable plates and screws in pediatric facial fractures. J Oral Maxillofac Surg (2005); 63:385-91.
14. Putney SD, Burke P. Improving protein therapeutics with sustained-release formulation. Nat Biotechnol (1998); 16: 153-7.
15. Tracy M. Development and scale-up of a microsphere protein delivery system. Biotechnol Prog (1998); 14:108-15.
16. Burgess DJ, Crommelin DJA, Hussain AS, Chen M, EUFEPS. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS PharmSci [serial online] (2004); 6:artículo 11. Disponible en: URL: http://www.pharmscitech.com.
17. Kent JS, Sanders LM, Lewis DH, Tice TR, inventors; SYNTEX INC (US), assignee. Microencapsulation of water soluble polypeptides. US Patent 207 864. 1985.
18. Lapka G, Mason NS, Thies C, inventors; Univ Washington (US), assignee. Process for prepartion of microcapsules. US Patent 4 622 244. 1986.
19. Orsolini P, Mauvernay R-Y, Deghenghi R, inventors; DEBIOPHARM SA (CH), assignee. Microencapsulation by phase separation of water-soluble medicaments. US Patent 4 673 595. 1987.
20. Lewis DD. Controlled release of bioactive agents from lactide/glycolide polymer. In: Chasin M, Langer R, editors. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker; 1990: 1-41.
21. Courveur P, Puisieux F. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Deliv Rev (1993); 10:141-62.
22. Thomasin C, Johansen P, Alder R, Bemsel R, Hottinger G, Altorfer H, et al. A contribution to overcoming the problem of residual solvents in biodegradable micropheres prepared by coacervation. Eur J Pharm Biopharm (1996); 42:16-24.
23. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/ evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release (2005); 102:313-32.
24. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release (2003); 90:261-80.
25. Gander B, Wehrli E, Alder R, Merkle P. Quality improvement of spray-dried, protein loaded D,L-PLA microspheres by appropiate polymer solvent selection. J Microencapsul (1995); 12:83-97.
26. Johansen P, Merkle HP, Gander B. Technological considerations related to the up-scaling of protein microencapsulation by spray-drying. Eur J Pharm Biopharm (2000); 50:413-7.
27. Longo WE, McCluskey RA, P Goldberg E, inventors; Univ Florida (US), assignee. Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and method of preparation thereof. US Patent 4 871 716. 1989.
28. DeLuca P, Rypacek F, inventors; Univ Kentucky Res Found (US), assignee. Biodegradable microspheres as carrier for macromolecules. EP 0 245 820. 1991.
29. Cohen S, Bano C, Chow MB, Allcock HR, Langer R, inventors; Massachusetts Inst Technology (US); Penn State Res Found (US), assignees. Ionically cross-linked polymeric microcapsules. US Patent 5 308 701. 1994.
30. Calvo P, Sánchez A, Martínez J, López MI, Calonge M, Pastor JC, et al. Polyester nanocapsules as new topical ocular delivery systems for Cyclosporin A. Pharm Res (1996); 13:311-5.
31. Sánchez A, Alonso MJ. Poly(D,L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood/plasma levels of subcutaneously injected Cyclosporin A. Eur J Pharm Biopharm (1995); 41:31-7.
32. Orsolini P, inventors; Debio Recherche Pharmaceutique S.A., assignee. Process for the preparation of microspheres made of a biodegradable polymeric material. US Patent 5 445 832. 1995.
33. Meinel L, Illi OE, Zapf J, Malfanti M, Merkle HP, Gander B. Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres. J Control Release (2001); 70:193-202.
34. Pérez C, Jesús PD, Griebenow K. Preservation of lysozyme structure and function upon encapsulation and release from poly(lactic-co- glycolic) acid microspheres prepared by the water-in-oil-in-water method. Int J Pharm (2002); 248: 193-206.
35. 2/ water interface and upon water-in-oil-in-water encapsulation in PLGA microspheres. J Control Release (2003); 89:71-85.
36. Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y, et al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release (2006); 112:35-42.
37. Cleland JL, Duenas E, Dougherty A, Marian M, Yang J, Wilson M, et al. Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect. J Control Release (1997); 49:193-205.
38. Péan JM, Venier-Julienne MC, Boury F, Menei P, Benoit D, Benoit JP. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some encapsulation parameters on encapsulated NGF stability. J Control Release (1998); 56:175-87.
39. Péan JM, F. Boury MCV-J, Menei P, Proust JE, Benoit JP. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm Res (1999); 16:1294-9.
40. Yang YY, Chia HH, Chung TS. Effect of preparation temperature on the characteristics and release profile of PLGA containing protein fabricated by double emulsion solvent extraction/evaporation. J Control Release (2000); 69:81-96.
41. Weert MV, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res (2000); 17:1159-67.
42. Pistel KF, Bittner B, Koll H, Winter G, Kissel T. Biodegradable recombinant human erythropoietin loaded microspheres prepared from linear and star-branched block copolymers: Influence of encapsulation technique end polymer composition on particle characateristics. J Control Release (1999); 59:309-25.
43. Zhou S, Deng X, He S, Li X, Jia W, Wei D, et al. Study on biodegradable microspheres containing recombinant interferon-alpha-2a. J Pharm Pharmacol (2002); 54:1287-92.
44. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly (lactic/ glycolic acid) microspheres. Pharm Res (1991); 8:713-20.
45. Herbert P, Murphy K, Johnson O, Dong N, Jaworowicz W, Tracy M, et al. A large-scale process to produce microencapsulated proteins. Pharm Res (1998); 15:357-61.
46. Lam XM, Duenas ET, Dougherty AL, Levin N, Cleland JL. Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. J Control Release (2000); 67:281-92.
47. Kim HK, Park TG. Comparative study on sustained release of human growth hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D, L-lactic-co-glycolic acid) microspheres: morphological effect on protein release. J Control Release (2004); 98:115-25.
48. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable Long-Circulating Polimeric Nanospheres. Science (1994); 263:1600-3.
49. Quellec P, Gref R, Perrin L, Dellacherie E, Sommer F, Verbavatz JM, et al. Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J Biomed Mater Res (1998); 42:45-54.
50. Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic enviroment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res (2000); 17:100-6.
51. Weert MV, Hof RV, Weerd JV, Heeren RMA, Posthuma G, Hennink WF, et al. Lysozyme distribution and conformation in a biodegradable polymer matrix as determined by FTIR techniques. J Control Release (2000); 68:31-40.
52. Rahman NA, Mathiowitz E. Localization of bovine serum albumin in double-walled microspheres. J Control Release (2004); 94:163-75.
53. Bitz C, Doelker E. Influence of the preparation method on residual solvents in biodegradable microspheres. Int J Pharm (1996); 131:171-81.
54. Meng FT, Ma GH, Qiu W, Su ZG. W/O/ W double emulsion technique using ethyl acetate as organic solvent: effects of its diffusion rate on the characteristics of microparticles. J Control Release (2003); 91:407-16.
55. Pistel KF, Kissel T. Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique. J Microencapsul (2000); 17:467-83.
56. Bernstein H, Mathiowitz E, Morrel E, Brickner A, inventors; Alkermes Inc. assignee. Erythropoietin drug delivery system. WO Patent 9 325 221. 1993.
57. Khan A, Tracy MA, Bernstein H, inventors; Alkermes Inc., assignee. Composition and method for the controlled release of metal cation-stabilized interferon. US Patent 5 711 968. 1998.
58. Alonso MJ, Gupta RK, Min C, Siber GR, Langer R. Biodegradable microspheres controlled-release tetanus toxoid delivery systems. Vaccine (1994); 12:299-312.
59. Haznedar S, Dortunc B. Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide. Int J Pharm (2004); 269:131-40.
60. Sun SW, Jeong YI, Jung SW, Kim SH. Characterization of FITC-albumin encapsulated poly(dl-lactide-co-glycolide) microspheres and its release characteristics. J Microencapsul (2003); 20:479-88.
61. Cheng YH, Illum L, Davis SS. A poly (d,l-lactide-co-glycolide) microsphere depot system for delivery of haloperidol. J Control Release (1998); 55:203-12.
62. Péan JM, Venier-Julienne MC, Filmon R, Sergent M, Phan-Tan-Luu R, Benoit JP. Optimization of HSA and NGF encapsulation yields in PLGA microparticles. Int J Pharm (1998); 166:105-15.
63. Kempen DHR, Lu L, Zhu X, Kim C, Jabbari E, Dhert WJA et al. Development of biodegradable poly(propylene fumarate)/poly(lactic-co-glycolic acid) blend microspheres. I. Preparation and characterization. J Biomed Mater Res Part A (2004); 70A:283-92.
64. Lee SC, Oh JT, Jang MH, Chung SI. Quantitative analysis of polyvinyl alcohol on the surface of poly(D,L-lactide-co-glycolide) microparticles prepared by solvent evapo-ration method: effect of particle size and PVA concentration. J Control Release (1999); 59:123-32.
65. Mateovic T, Kriznar B, Bogataj M, Mrhar A. The influence of stirring rate on biopharmaceutical properties of Eudragit RS microspheres. J Microencapsul (2002); 19:29-36.
66. Dinarvand R, Moghadam SH, Mohammadyari-Fard L, Atyabi F. Preparation of biodegradable microspheres and matrix devices containing naltrexone. AAPS Pharm SciTech [serial online] 2003; 4:E34. Disponible en: URL: http://www. pharmscitech.com.
67. Sánchez A, Villamayor B, Guo Y, McIver J, Alonso MJ. Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres. Int J Pharm (1999); 185:255-66.
68. Cleland JL. Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines. Biotechnol Prog (1998); 14:102-7.
69. Srinivasan C, Katare YK, Muthukumaran T, Panda AK. Effect of additives on encapsulation efficiency, stability and bioactivity of entrapped lysozyme from biodegradable polymer particles. J Microencapsul (2005); 22:127-38.
70. Impurities: Guidelinefor residual solvents. ICH harmonised tripartite guideline. In: International Conference on Harmonisation of Technical Requeriments for Registration of Pharmaceuticals for Human Use. 1997.
71. B'Hymer C. Residual Solvent Testing: A review of gas-chromatographic and alternative techniques. Pharm Res 2003; 20:337-44.
72. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm (2004); 282:1-18.
73. Yang J, Cleland JL. Factors affecting the in vitro release of recombinant human interferon-γ (rhIFN-γ) from PLGA microspheres. J Pharm Sci (1997); 86:908-14.
74. Blanco-Prieto J, Besseghir K, Orsolini P, Heimgartner F, Deuschel C, Merkle HP, et al. Importance of the test medium for the release kinetics of a somatostatin analogue from poly (DL-lactide-co-glycolide) microspheres. Int J Pharm (1999); 184:243-50.
75. Burgess DJ, Hussain AS, Ingallinera TS, Chen M. Assuring quality and performance of sustained and controlled release parenterals: AAPS Workshop Report, Cospon-sored by FDA and USP. Pharm Res (2002); 19:1761-8.
76. Dani BA, DeLuca PP. Preparation, characterization, and in vivo evaluation of Salmon Calcitonin microspheres. AAPS PharmSciTech [serial online] 2001;2:artículo 22. Disponible en: URL: http://www.pharmscitech.com.
77. Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med (1996); 2:795-9.
78. Park TG, Lu W, Crotts G. Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (D,L-lactic acid-co-glycolic acid) microspheres. J Control Release (1995); 33:211-22.
79. Kim HK, Park TG. Microencapsulation of human growth hormone within biodegradable polyester microspheres: Protein aggregation stability and incomplete release mechanism. Biotechnol Bioeng (1999); 65: 661-7.
80. Ravivarapu HB, Burton K, DeLuca PP. Polymer and microsphere blending to alter the release of a peptide from PLGA mi-crospheres. Eur J Pharm Biopharm (2000); 50:263-70.
81. Woo BH, Kostanski JW, Gebrekidan S, Dani BA, Thanoo BC, DeLuca PP. Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide) leuprolide microspheres. J Control Release (2001); 75:307-15.
82. Deng XM, Li XH, Yuan ML, Xiong CD, Huang ZT, Jia WX, et al. Optimization of preparative conditions for poly-DL-lactide-polyethylene glycol microspheres with entrapped Vibrio Cholera antigens. J Control Release (1999); 58:123-31.
83. Yang TH, Dong A, Meyer J, Johnson OL, Cleland JL, Carpenter JF. Use of Infrared Spectroscopy to assess secondary structure of Human Growth Hormone within biodegradable microspheres. J Pharm Sci (1999); 88:161-5.
84. Fu K, Griebenow K, Hsieh L, Klibanov AM, Langer R. FTIR characterization of the secondary structure of proteins encapsulated within PLGA microspheres. J Control Release (1999); 58:357-66.
85. Capan Y, Jiang G, Giovagnoli S, Na KH, DeLuca PP. Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone. AAPS PharmSciTech [serial online] 2003; 4:artículo 28. Disponible en: URL: http:/ /www.pharmscitech.com.
86. Cleland JL. Design and production of single immunization vaccines using polylactide polyglycolide microsphere system. In: Powell MF, Newman M, editors. Vaccine Design: The Subunit Approach. New York: Plenum Publishing; 1995. p.439-72.
87. Parikh RH, Parikh JR, Dubey RR, Soni HN, Kapadia KN. Poly(D,L-lactide-co- glycolide) microspheres containing 5-Fluorouracil: Optimization of process parameters. AAPS PharmSciTech [serial online] 2003; 4:Artículo 13. Disponible en: URL: http://www. pharmscitech.com.
88. 3 factorial design. AAPS PharmSciTech [serial online] 2003; 4:artículo 71. Disponible en: URL: http://www.pharmscitech.com.
89. Langer R, Cleland JL, Hanes J. New stability in controlled-release systems. Nat Biotechnol (2000); 18:24-5.
90. Fu K, Klibanov AM, Langer R. Protein stability in controlled-release systems. Nat Biotechnol (2000); 18:24-5.
91. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev (2005); 57:391-410.